share_log

Senti Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Collins James J.

Senti Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Collins James J.

Senti Biosciences | 4:持股變動聲明-董事 Collins James J.
美股sec公告 ·  07/12 16:18
Moomoo AI 已提取核心訊息
James J. Collins, associated with Senti Biosciences, Inc. (SNTI.US), was involved in a transaction with the company's stock on July 10, 2024. The specific details regarding the nature of the transaction, such as the number of shares traded, the transaction price, and the resulting ownership stake, have not been disclosed. This information is crucial for investors to understand the implications of insider actions on their investment decisions.
James J. Collins, associated with Senti Biosciences, Inc. (SNTI.US), was involved in a transaction with the company's stock on July 10, 2024. The specific details regarding the nature of the transaction, such as the number of shares traded, the transaction price, and the resulting ownership stake, have not been disclosed. This information is crucial for investors to understand the implications of insider actions on their investment decisions.
詹姆斯·柯林斯與Senti Biosciences, Inc. (SNTI.US)有關,於2024年7月10日與該公司的股票進行了交易。具體交易細節,如交易股數、交易價格和持股比例等,尚未披露。對於投資者了解內部人員行爲對其投資決策的影響,這些信息至關重要。
詹姆斯·柯林斯與Senti Biosciences, Inc. (SNTI.US)有關,於2024年7月10日與該公司的股票進行了交易。具體交易細節,如交易股數、交易價格和持股比例等,尚未披露。對於投資者了解內部人員行爲對其投資決策的影響,這些信息至關重要。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息